公开(公告)号：US20170218070A1

公开(公告)日：2017-08-03

申请号：US15401971

申请日：2017-01-09

申请人： Merck Patent GmbH

发明人： Axel Hoffmann ,  Heinrich Lannert ,  Klaus Brischwein ,  Frederic Christian Pipp ,  Juergen Reindl ,  Karin Groll ,  Michael Zuehlsdorf ,  Otmar Pfaff ,  Sabine Raab ,  Ulrike Dau ,  Benoit Destenaves

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2839 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2848 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76

摘要： The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.

公开(公告)号：US20190263913A1

公开(公告)日：2019-08-29

申请号：US16258289

申请日：2019-01-25

申请人： Merck Patent GmbH

发明人： Axel Hoffmann ,  Heinrich Lannert ,  Klaus Brischwein ,  Frederic Christian Pipp ,  Juergen Reindl ,  Karin Groll ,  Michael Zuehlsdorf ,  Otmar Pfaff ,  Sabine Raab ,  Ulrike Dau ,  Benoit Destenaves

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06

摘要： The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.